Dr. Ned Sharpless on Hatteras Discovery, China's Biotech Rise, and FDA Reform Needs
Summary
Dr. Ned Sharpless discusses his new role at Hatteras Discovery, a seed-stage fund focused on early-stage academic science, contrasting it with his previous fund's structure. He argues that China's advancements in biotech and lower-cost discovery infrastructure are reshaping US investment flows, warning that protectionist policies like the COINS Act could harm US innovation. Sharpless highlights Japan's Chugai Pharmaceuticals as a model for high-quality, in-house discovery, contrasting it with the US trend of outsourcing R&D to early-stage biotechs. He also addresses the US advantage in attracting global talent, dismissing 'brain drain' narratives as overstated. Finally, he advocates for formal FDA rulemaking over executive discretion to ensure regulatory certainty for biotech investors.
Key takeaways
- 1 outsources a lot of their science and and and acquires you know, early stage biotech. companies uh for innovation.
Unidentified speaker (speaker_1) · 30:47
Episode sections
- 0:56 – 9:25
Hatteras Discovery and Early-Stage Biotech Investing
Dr. Ned Sharpless discusses his new role as Managing Director of Hatteras Discovery, a seed-stage fund focused on building companies from academic science. He contrasts this with his previous fund, Jupiter BioVentures, noting that Hatteras allows him to focus purely on early-stage discovery while leveraging other Hatteras funds for follow-on investments.
- 9:25 – 28:35
China's Rise in Biotech and Investment Restrictions
Sharpless addresses the impact of China's growing biotech capabilities on US investment flows, noting that early-stage US capital is shifting due to concerns about Chinese emulation. He critiques the proposed COINS Act, arguing that protectionist measures could harm US patients and innovation by limiting access to global scientific collaboration and lower-cost discovery tools.
- 28:35 – 29:42
Japan and Chugai Pharmaceuticals
Sharpless shares insights from a recent trip to Japan, highlighting his advisory role with Chugai Pharmaceuticals. He praises the company's in-house discovery model and cultural emphasis on quality, citing the Lasker Award-winning development of Hemlibra as an example of innovative Japanese biotech.
- 29:42 – 32:42
Japanese vs. US Biotech R&D Models
Speaker 1 contrasts the protracted, high-budget molecule screening approach of a Japanese company (Chu Gai) with the rushed, underfunded nature of US early-stage biotech. He notes that Big Pharma now largely outsources science and acquires early-stage companies rather than building molecules internally.
- 32:42 – 35:00
US Advantage in Attracting Global Talent
Speaker 1 argues the US retains a significant advantage over China and Japan in attracting top international scientists due to higher salaries, better grant funding, and a welcoming culture. He cites Japan's strategy of opening R&D facilities in Singapore to access global talent as a model the US should watch.
- 35:00 – 39:09
Debunking 'Brain Drain' Narratives
Speaker 1 dismisses media reports of a massive exodus of scientists from the US as 'yellow journalism' and overblown. He attributes most departures to personal reasons (family, returning home) rather than a collapse of US science, noting that European grants are significantly smaller than US NIH funding.
- 39:09 – 43:21
Impact of Divided Government on Biotech Policy
Speaker 1 suggests that divided government forces compromise, which can be beneficial for bipartisan-supported agencies like the NIH and FDA. He warns that must-pass legislation like PDUFA and appropriations bills may become 'Christmas trees' for unrelated political priorities, creating uncertainty.
- 43:21 – 46:43
FDA Regulatory Certainty vs. Executive Discretion
Speaker 1 criticizes reliance on FDA proclamations and executive orders (e.g., enforcement discretion for peptides) as lacking longevity. He advocates for formal rulemaking or legislation to provide certainty, citing the 'Trial Blazer' pilot and the concept of Qualified Research Institutes (QRIs) as promising pathways.
- 46:43 – 50:42
FDA Leadership and Political Risks
Speaker 1 discusses the confirmation of Heidi Overton as FDA Commissioner, noting the importance of a confirmed leader for stability. He warns that non-medical product issues (food safety, tobacco, vapes) and internal political tensions (e.g., RFK Jr. influence) pose significant risks to the Commissioner's focus and tenure.
Claims worth verifying
Hatteras was the initial investor in G1 Therapeutics, which went public and had a drug approved for lung cancer.
Unidentified speaker (speaker_1) ·3:30
How to verify: Check SEC filings (e.g., S-1 or 10-K) for G1 Therapeutics to identify initial investors and FDA approval records for its lung cancer drug. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
Primary sourceJupiter BioVentures was launched in 2022 and deployed most of its capital into early-stage companies.
Unidentified speaker (speaker_1) ·2:31
How to verify: Review press releases or SEC filings (Form ADV) for Jupiter BioVentures to confirm launch date and portfolio history. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
Primary sourceThe COINS Act is a draft rule proposed to limit US investment in Chinese for-profit biotech companies.
Unidentified speaker (speaker_1) ·16:38
How to verify: Search US Treasury Department or White House press releases for the 'COINS Act' or 'China Investment and National Security' draft rules. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
Chugai Pharmaceuticals scientists won the Lasker Award for developing Hemlibra.
Unidentified speaker (UNKNOWN) ·29:22
How to verify: Check the Lasker Foundation website for past winners and the specific citation for the Lasker Award related to Hemlibra. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
In 2018, the intelligence community told Sharpless that Chinese research capabilities were a threat to US hegemony.
Unidentified speaker (speaker_1) ·11:23
How to verify: Verify Sharpless's tenure as NCI Director (2018-2026) via NCI.gov and check public records or news reports from that period regarding US-China scientific competition. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
China offers cheaper and faster toxicology testing and early clinical trials compared to the US.
Unidentified speaker (speaker_1) ·13:24
How to verify: Compare industry reports on CRO pricing and trial timelines from sources like EvaluatePharma or IQVIA for US vs. China markets. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
G1 Therapeutics was founded in 2008 out of Sharpless's lab.
Unidentified speaker (speaker_1) ·3:30
How to verify: Check SEC filings for G1 Therapeutics or company history pages for founding date and founder information. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
Primary sourceThe US still has an advantage in attracting international trainees compared to China.
Unidentified speaker (UNKNOWN) ·12:45
How to verify: Analyze data from the National Science Foundation (NSF) or Department of Education on international student enrollment in US vs. Chinese universities. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
FDA inspectors cannot conduct unannounced inspections in China as easily as in Europe or Australia.
Unidentified speaker (speaker_1) ·27:09
How to verify: Review FDA Foreign Inspection Manual or recent FDA warning letters and inspection reports regarding Chinese clinical trial sites. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
Chugai Pharmaceuticals relies on in-house early drug discovery work.
Unidentified speaker (UNKNOWN) ·28:58
How to verify: Check Chugai Pharmaceuticals' annual reports or corporate presentations detailing their R&D model and internal capabilities. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
A Japanese company screened ~10,000 versions of a molecule to create a hemophilia treatment that is simpler, cheaper, and more effective than gene therapy.
Unidentified speaker (speaker_1) ·29:42
How to verify: Review clinical trial data and company press releases for the specific hemophilia drug discussed (likely Valneva's or a similar Japanese biotech firm's asset) to confirm the screening scale and efficacy claims. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
Big Pharma now largely outsources science and acquires early-stage biotech companies for innovation.
Unidentified speaker (speaker_1) ·30:47
How to verify: Analyze M&A transaction databases (e.g., PitchBook, Crunchbase) and R&D expenditure reports from major pharma companies (e.g., Pfizer, Merck) to track the ratio of internal R&D vs. in-licensing/acquisitions over the last 10 years. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
The US has a significant advantage in attracting foreign scientists due to higher salaries and better grant funding compared to Europe.
Unidentified speaker (UNKNOWN) ·32:42
How to verify: Compare salary surveys for postdocs and senior scientists in the US (e.g., National Postdoctoral Association) vs. EU countries (e.g., Eurofound) and NIH grant award data vs. European Research Council (ERC) grants. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
Media reports of a massive 'brain drain' of scientists from the US are 'yellow journalism' and overblown.
Unidentified speaker (UNKNOWN) ·35:00
How to verify: Analyze NIH grant award data and publication trends by nationality over the past 5 years to check for actual decline in foreign-born researchers in US institutions. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
European grant funding is significantly lower than US funding (e.g., $50k in Germany vs. 10x in US).
Unidentified speaker (speaker_1) ·37:48
How to verify: Compare average grant sizes from the European Research Council (ERC) or national agencies (DFG) vs. NIH R01 grants using public award databases. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
Divided government forces compromise, which benefits bipartisan-supported agencies like NIH and FDA.
Unidentified speaker (speaker_1) ·40:03
How to verify: Review legislative history and funding levels for NIH/FDA during periods of divided vs. unified government (e.g., 2026-2026 vs. 2026-2026) to assess stability and continuity of funding. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
FDA enforcement discretion policies (e.g., for peptides) lack longevity and can be reversed by a new Secretary.
Unidentified speaker (speaker_1) ·43:54
How to verify: Track FDA letters and guidance documents regarding enforcement discretion policies and their duration/change under different administrations (e.g., HHS Secretaries under Trump vs. Biden). For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
The 'Qualified Research Institute' (QRI) pilot aims to outsource regulatory processing for first-in-human trials to third parties.
Unidentified speaker (speaker_1) ·46:03
How to verify: Review the FDA's IND Pilot Program documentation and QRI pilot results published on the FDA website to confirm the scope and objectives of the QRI initiative. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
Heidi Overton is a qualified candidate for FDA Commissioner, supported by an op-ed from Scott Gottlieb and Mark McClellan.
Unidentified speaker (speaker_1) ·46:43
How to verify: Search for the op-ed by Scott Gottlieb and Mark McClellan in major news outlets (e.g., Wall Street Journal, NYT) to verify their endorsement and the claims made about Overton's qualifications. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
Internal tensions involving RFK Jr. and the White House could impact FDA leadership and policy.
Unidentified speaker (speaker_1) ·48:55
How to verify: Review news reports and official statements regarding RFK Jr.'s role in the administration and any reported conflicts or policy shifts affecting the FDA. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
Do your own research
- Verify the operational structure and portfolio of Hatteras Discovery One and its investment in G1 Therapeutics via SEC filings and company press releases.
- Review the text of the proposed COINS Act draft rule and Sharpless's critique regarding its impact on US investment flows.
- Compare R&D expenditure per candidate and molecule screening volumes in US vs. Japanese biotech firms using 10-K filings from major pharma and biotech companies.
- Analyze NIH grant award data and publication trends by nationality to assess the validity of 'brain drain' narratives.
- Check FDA guidance documents and letters regarding the 'Qualified Research Institute' (QRI) pilot program and its current status.
- Review legislative history and funding levels for NIH/FDA during periods of divided vs. unified government to assess policy stability.
- Compare median postdoc/senior scientist salaries in US academia/biotech vs. EU countries using data from the National Postdoctoral Association or EU salary surveys.
- Track FDA enforcement discretion policies (e.g., for peptides) and their duration/change under different administrations to assess regulatory longevity.
Full transcriptexpand
0:00Unidentified speaker (UNKNOWN): At
0:00John Stanford: Making Medicine, we're reporting on the headlines, not making medical recommendations. For personal health questions, always ask your doctor. Nothing in this episode constitutes investment, financial, or legal advice. Consult your own advisors before making decisions.
0:16Unidentified speaker (speaker_1): My whole life's work has been about trying to help people not die of cancer. And if somebody brought me a great idea to like help people not if you know some seven-year-old seven year old didn't doesn't have to die of leukemia and it comes from Shanghai I don't care you know I I want to make progress for patients
0:36John Stanford: welcome back to the Making Medicine Podcast where science, policy, and innovation meet. I'm your host, John Stanford. Today I'm glad to welcome back Dr. Ned Sharpless. Longtime listeners and frankly everyone in the biotech community likely know Ned from his time directing the National Cancer Institute and serving as acting commissioner of the FDA. Before that, he was a cancer researcher at UNC's Lineberger Comprehensive Cancer Center, and he's the founder of G1 Therapeutics. Since we last talked, Ned's name was floated for the next FDA commissioner under the Trump administration. But instead, he's taken on a new role as managing director of Hack. Hatteras Discovery, the firm's seed stage effort to build new companies from academic science. It's a role that brings him back to where his own career started, turning university research into medicines that reach patients. But now he's doing it as an investor with what he learned as a researcher, founder, and regulator. We'll talk about the funding climate for biotech, China, and restrictions on outbound investment. what the new Congress means for drug pricing, his recent trip to Japan, and of course, he's the right person to talk to about Padofa reauthorization that'll be a focus of Congress next year. It's a lot to cover, so let's get into the show. Ned, welcome to the show. It's
1:54Unidentified speaker (speaker_1): great to be back. It's good to see you again and talk about all things, you know, D DC C and drug discovery.
1:58John Stanford: Yeah, it really really is. Welcome back to the show because uh we we checked the analytics, you're Your last time on the on the show was one of our best performing episodes, so no pressure, but we're looking for lots of pearls of wisdom today. And you'll you'll have some in the context of your new role, no doubt. And so uh when you were with us previously, you hadn't taken on this role at Hatteras Discovery. Can you tell us a little bit about um what you're doing and what was so attractive? to you in joining up and taking on that role?
2:31Unidentified speaker (speaker_1): Sure. I um you know left government in 22 and I had been running a fund called Jupiter BioVentures for the last couple of years, which uh had deployed most of its capital to start early stage companies. So it really, really like the first money in, the first investor, often academic startups. You know, it's really fun because you're like, look. looking at science and you know, bans on gels and data, and you know, trying to decide if these are good ideas to develop commercial products. And uh, you know, we had deployed most of that capital and started a bunch of companies. We have two going concerns. All the money left in that fund is solely earmarked for follow-on investing in those companies that are up and running, Calvary and Persistence. And so uh, you know, we've we've been discussing. been discussing raising Jupiter 2 because just starting new companies is really the fun part of this business. And we haven't started a new company out of Jupiter in more than a year. And uh while sort of thinking about you know raising that second fund, uh, you know, I began discussing the idea of you know doing similar work with Hatteras with my old friend Clay Thorpe. So uh Hatteras was the initial investor in a company called G1 Therapeutics that I started out of my lab in you know 2008. Uh our first investor. was my mom, but Hatteras was the first real investor, I would like to say. And it was a great experience. That company went public and the drug got approved, and it's now used in lung cancer. And so, you know,
3:50the appeal of working with Christy Schaefer and Clay Thorpe and the rest of the Hatteras team again was very strong. And one other thing I really liked about it is, you know, at this stage of my career, I sort of like the North Carolina. Southeastern focus. Uh, you know, I've uh I've done enough starting companies in San Diego and uh you know Toronto and stuff now, you know, having a little that's not to say that Hatteras doesn't do that. I mean certainly they look at companies all over the world, but you know, having a little more of uh Duke, UNC, NC State, Emery, uh UVA, uh Johns Hopkins, you
4:25Unidentified speaker (UNKNOWN): know,
4:25Unidentified speaker (speaker_1): the looking at those places uh for great ideas uh is is nice. You know, I I I'm a North Carolina guy and I I like to build companies that particularly benefit the state. So I think that's been appealing as well.
4:36Unidentified speaker (UNKNOWN): Yeah,
4:36John Stanford: I mean, I think the team over there is incredible and talk about sort of the flagship North Carolina. Is it new for Hatteras to be, you know, uh the five 5 AM guys launched four 459 fifty nine for a moment there? Um some other folks have wandered and sort of had these setups. Was this something Hatteras was doing or really under your leadership, are they going to be looking even earlier than they had typically been looking?
5:02Unidentified speaker (speaker_1): Right. So so Hatteras is uh you know invests in health tech, med tech, and then all stages of biotech. Uh and they have done some early stuff in the past. So in in one of their prior funds, they had a discovery fund. So in in an it it was called at Disco, Hatter's Discovery. We've always thought we needed like a mirror ball or something for Hatteris.
5:20John Stanford: We do need something.
5:21Unidentified speaker (UNKNOWN): So Christy
5:22Unidentified speaker (speaker_1): Schaefer was the uh managing director of Hatter's Discovery One, and that was the vehicle that invested in G1. So and the model was not solely to invest, but also to bring in expertise and leadership and kind of take a very large operational role in these very early stage act. academic companies. And and that fund worked out really well. You know, it was had very good returns for Hatteras, delivered a bunch of deals that got, you know, follow-on investing, led to multiple FDA approved products. And so I think but you know there's a cyclic nature of this business and there's personnel issues. And so so Hatteras I think had wanted to do that again, but really it hadn't been the right time. And so that's actually what Clay approached me about. He
6:00Unidentified speaker (UNKNOWN): said
6:00Unidentified speaker (speaker_1): we want to do another discovery fund. We want it to be, you know, uh, you know, relatively large for this stage of investing fund. And uh, you know, the work would be very similar to what I've been doing in Jupiter, you
6:13Unidentified speaker (UNKNOWN): know,
6:13Unidentified speaker (speaker_1): the early stage ideas, mostly academics, but not solely academics, and and and then playing both you know an investing role, but perhaps more importantly and more fun for me as an operational role to really get involved in these companies and and try help them get set up
6:28Unidentified speaker (UNKNOWN): and
6:28Unidentified speaker (speaker_1): you know figure out how to deploy the technology. And so, you know, it's it's uh one of the things that's nice about a Hatteras as opposed to the Jupyter model is that the Jupyter model, you have to hold so much of your fund for follow-on investing. That's that's a
6:41John Stanford: necessary
6:42Unidentified speaker (speaker_1): evil or condition of venture capital. With Hatteras, there is the big fund, you
6:46Unidentified speaker (UNKNOWN): know,
6:46Unidentified speaker (speaker_1): Hatteras' other funds to invest follow-on. follow on. And so you can really focus the discovery. Fund on early stage stuff and get them stood up. And then there are other funds from Hatteras and Syndicate partners to you know come in later if needed. So it's you know a very attractive thing to be doing, and I really like this work. And uh and so I'm excited about you know getting this uh this effort really going.
7:07John Stanford: Any investments to date? Are you still in the early days?
7:10Unidentified speaker (speaker_1): Still in the early days. You know, I've certainly been inundated with ideas and we're collecting. That's great. You know, I I but one important point though, I think that is, you know, and it it's interesting as to why this is, but it's still a really good time to be investing in early stage biotech. So, you know, when I started Jupiter in 22, it was just, you know, nuclear winter for early stage biotech. I mean,
7:33Unidentified speaker (UNKNOWN): nobody
7:34Unidentified speaker (speaker_1): was investing. It was impossible to raise money. And so with just a little bit of capital, we were, you know. able to see a lot of great ideas from very accomplished, famous scientists and serial entrepreneurs. And that that is still true. It is certainly a better biotech investing environment today than it was, you know, a few years ago. But if you look at where the money's going, it's mostly going into these large, you know, mega A rounds for clinical stage assets that have been substantially risked. And and the early stage uh stuff is still not getting a lot of love. So if you have a fund that says I I unabashedly, you know, full-throated endorsement of early stage biotech, you know, they're just a lot of people who want to send you ideas. And so we are, you know, carefully going through options and considering what things we should be doing. We think about half the funds will be in oncology, but half will, I mean, half of the projects will be in oncology, but half will not. So we're looking at sort of all all therapeutic areas. And uh, you know, I think it's uh it's a really um still kind of a buyer's market in this space. Uh, you know, it's it's I had someone uh, you know, yesterday in fact ask me why I thought it was so, you know, why why the money's, you know, sort of going to the later stage stuff. And I, you know, I I suspect it's a a a a a a combination of many factors, but you know. one important one that I think
8:52is widely unappreciated is sort of the China risk. Is that early stage ideas that can be emulated uh by scientists in China are uh unattractive to venture capitalists at the moment because there's a feeling that there's just so much capacity over there and the ability to do clinical trials there so quickly that you really have to have something that's sort of novel and not, you know, uh a me too. looking product at all. And so so I think that a lot of the early stage stuff that used to get done in the United States is now, you know, people are looking for overseas deals. And that's one problem, but I don't think the only problem.
9:25John Stanford: Well, that's uh it that's certainly the topic, DeJorr. I want to come back to midterms and in the bigger blue wave conversation and get your take on that. But in our industry, it's actually not the midterms, it is China. It is this. coins proposal. It is restricting outbound investment. And I want to say we we we went back and we ran the tape. You were very prescient here. In when we talked 18 months ago, you had some really good points about people need to pay attention that the innovation in China is strong as ever. And you know, 18 months ago, it was only a handful of policy. policymakers that I think were were open to the idea that China's capabilities are as strong as ours, even in some places surpassing ours. So it was great to rewatch that conversation. How do you see this? There is a some effort back in Washington to try to wall off China and say, you know, we we want to slow it down. We don't want them. getting so far ahead. We don't want our investors looking over there.
10:32You know, how do you reconcile that with also your job of stewarding capital to find the best innovation and pull it forward? Is there a path to truly walling off China, or are we kidding ourselves with this proposal? Aaron Trevor
10:46Unidentified speaker (UNKNOWN): Powell Burrus Yeah,
10:46Unidentified speaker (speaker_1): I mean, I have you know it's a very complicated topic, and it really doesn't lend itself to second. sound bites. And unfortunately for China, people want sound bites. You
10:54Unidentified speaker (UNKNOWN): know,
10:54Unidentified speaker (speaker_1): I the politicians want to distill
10:56Unidentified speaker (UNKNOWN): it down
10:56Unidentified speaker (speaker_1): to sort of three-second proclamations, but it's a very complicated and intricate relationship. And I
11:03Unidentified speaker (UNKNOWN): I
11:03Unidentified speaker (speaker_1): I think uh you know uh sort of well-intended uh you know policy proposals that aren't carefully thought through could end up you know hurting things, both hurting uh drug discovery. in the United States as well as progress for patients. So I so I think this really needs thought and attention. I I'll tell you, you know, when I was uh director of the National Cancer Institute in sort of we'll say 2018, members
11:25Unidentified speaker (UNKNOWN): of
11:26Unidentified speaker (speaker_1): the intelligence community actually came to the NCI and said, you know, tell us what you think about Chinese research capabilities and uh, you know, is that progressing in the way uh and and and they were of the opinion that it was uh you know very advanced over there, and the labs were every bit as good as the United States, maybe even better in some areas, and that this was a real threat to sort of US hegemony and biomedical research. And at that time, I remember pushing back. I remember saying I think that there are some really great scientists in China, many of whom you know trained uh in our labs in the United States and have returned to China. But you know, the in terms of the innovation and cancer. in cancer at least that I was seeing, it wasn't, you know, as strong.
12:05Unidentified speaker (UNKNOWN): It
12:06Unidentified speaker (speaker_1): was a lot of Me Too stuff. And you know, there'd be a kinase inhibitor that was identified as a useful target and then there'd be 47 versions of it made in Shanghai. So it really was uh you know quite strong science in some respects, but but it was um
12:21Unidentified speaker (UNKNOWN): you know
12:21Unidentified speaker (speaker_1): still lacking in that critical innovation piece and it looked more kind of CRO driven to me. But that that's no longer true. I mean, now I think in the in the decades since then, uh, you know, Chinese science has continued to progress. Uh, I know by name personally, many of the strongest you know scientists in China running labs in oncology. They, as I said, used to work at Harvard at the Dana Farber when I was a postdoc. You know, so I these
12:45Unidentified speaker (UNKNOWN): people I've
12:45Unidentified speaker (speaker_1): known for years, they're very, very talented. They run big labs that have lots. of very well trained postdocs. They don't have quite the uh draw for international trainees the way the United States does. So they don't get the great trainees from Europe and Latin America and things like that. The United States does that. So we still have some advantages in terms of the openness of our training environment. But suffice it to say, there's really great scientists in China and really great innovation companies. coming out of China. In addition to the very significant sort of CRO capabilities, we'll call it. The ability to sort of road experiments at high scale that are routine aspects of early stage drug discovery, like toxicology testing in rodents or early clinical trials, certainly have been uh you know much easier to do and and much cheaper over in China. So I think that uh um you know there are formidable advantages. And uh you know how to deal with that. I I I think that um first off, it is a problem for American biotech. I think that uh you know we're seeing uh a lot of investment that used to go to American companies is now going to uh you know Chinese startups, basically. And every day you're seeing a large pharma deal with some. small Chinese
14:04company that was heretofore unknown for five products, for seven antibodies, for you know these large deals with lots of um you know uh you know capabilities to them. So you know that's investment that's not not going in the United States. And uh, you know, I'm old enough to remember when uh this is sort of how you know science kind of left Europe, right? Europe used to have
14:25Unidentified speaker (UNKNOWN): a
14:26Unidentified speaker (speaker_1): much more vibrant. kind of scientific scene than it has now. And a lot of that was the focus on America over Europe. And so I think we're at risk of sort of losing some of our leadership because the Chinese science has grown so strongly. Having said that, I think the United States still has some formidable advantages. I mentioned training as one. I think the NIH, you know, with its gigantic budget and the ability. to fund
14:51Unidentified speaker (UNKNOWN): kind of
14:51Unidentified speaker (speaker_1): unfettered early stage investigation is a real strength and something that we should, you know, hope and pray Congress continues to support in a robust bipartisan manner. I also think the um
15:04Unidentified speaker (UNKNOWN): you
15:04Unidentified speaker (speaker_1): know the access to the U.S. market is actually a really important lever that many Chinese assets want to work with American companies because they need access. to the US market and that's difficult for them for a variety of reasons. And so we certainly, you know, in my world as an early venture capitalist, you know, get assets from China that would like to start a US new company or part, you know, license to a US company, for example. So there are certainly products being made in China that You know, might be appealing to US investors and US startups. Similarly, the ability to work with Chinese scientists is very important for American startups. So the ability to get studies done at Wuxi or the various very talented CRO facilities in China is important. And I I would also say the ability to do early stage clinical trials in China has been important. Even though it's somewhat limited and it's um a a very evolving area, it's still, I think. for some ideas, you know, a great way to get you know proof of concept data
16:06in people. And that that's important and has been useful. So I so I think the relationship is really int intricate. It's important for American patients because you know they benefit from more rapid discoveries. And so I I think any sort of well-intended, you know, let's just stop this now is uh it could be damaging to science and progress for patients. So the the the the the the moment you know the the sort of policy issue of the day is the Coins Act, which is you know is is a draft rule basically uh that's been floated to significantly limit investment
16:40Unidentified speaker (UNKNOWN): uh
16:40Unidentified speaker (speaker_1): by uh US entities in Chinese uh uh for-profit you know, biotech companies. It's actually in targeted a number of uh areas, and I think people were surprised. that biotech was included to the extent uh that it was, that went much more robustly than I think we expected. Um, you know, it's a draft rule. We'll see what the final, you know, if a final rule ever emerges, what it says. I I I think there's been a bit of pushback. I I I there's some aspects of the rule that looked unworkable to me. You know, just how do you
17:11Unidentified speaker (UNKNOWN): you
17:11Unidentified speaker (speaker_1): allow an out-and-out out and out acquisition, but not invest, you
17:13Unidentified speaker (UNKNOWN): know,
17:13Unidentified speaker (speaker_1): there are their licensing. deals, for example, and you know they're there, you know, so so making sure it's just sort of good policy and would even work is important. But I I um it makes me a little nervous that uh you know measures that look protectionist and with no other benefit uh are um you know potentially uh bad for patients. Certainly there are uh reasons to control investment in China in certain areas and to make sure that um, you know, the relationship in terms of Chinese science and scientific exchange, you know, things like AI and you know, cybersecurity and things like that make perfect sense to me. There even are a few topics in biomedical research, including you know, biodefense assets and things like that, that where I
17:55John Stanford: think
17:56Unidentified speaker (speaker_1): some Congress has some interest in placing controls, but you know, measures that are that appear solely protectionist to sort of prop up American. biomedical science, I don't think are a good idea. And I think it's a tough sell to the American public. It's like, hey, there's this great drug invented in China, but we don't want to let it in the US market because we're worried uh it might, you know, we might lose jobs in RTP or something. I don't I don't think that's a a a good message. Uh I I think we have to tell the American public Look, uh the reason to invest in American biomotor biomedical search is 'cause is because it's the best. You know, 'cause know, because we're making the most progress for patients and and so there there are probably some things we can do in the United States to make uh sure that we remain competitive in terms of biomedical research. But you know, walling off China and hoping they go away is uh is um, in my my view, not a good solution.
18:39John Stanford: I see you avoided the sound bites and gave what I think is one of the best answers on on the question at hand. I'm I'm curious, uh inside the walls at Hatteras if policy. comes up, does everybody just kind of look down and say, Yeah, let's let's let's go to Sharpless. He's uh he he's the policy guy. He he's got it.
18:58Unidentified speaker (speaker_1): I I mean you
18:59Unidentified speaker (UNKNOWN): know,
18:59Unidentified speaker (speaker_1): venture capitalists are always very opinionated. So there's there's it's not a as we can tell from Twitter, there are you know, there are plenty of VC opinions on every topic. So there's no shortage of opinions. But I mean, I think the reality is if you're investing in early stage biotech, uh and company creation in the United States, you know, you have a lot of uh interest in the in what you can do in China. You know, can you have Chinese investors? Can you license Chinese assets? Can you use Chinese CROs? And so things that can you do clinical trials in China? You know, these are really important things to know. And uh, you know, decisions in this business are made, you know, with with a decade. you know, sort of window time frame often. And if if that you know relationship is going to radically change in the future, uh, you know, it's important, it's material to your company creation today. So I think that uh, you know, we're all watching these areas, uh, wondering what's going to happen. And uh certainly I understand some of the intent here of Congress, but you know, w and and and the executive branch, but I also you know worry about the possibility for overreach. Aaron
20:07Unidentified speaker (UNKNOWN): Powell
20:07John Stanford: When you see, is that something in your remit? You know, when you think about uh hat disco two, as I'll try to call it. Um do you look globally? Are you looking regionally or only in the US? Or would you entertain um assets in the earliest days out of China? Aaron
20:23Unidentified speaker (UNKNOWN): Powell
20:23Unidentified speaker (speaker_1): Yeah, you know, I mean my my whole life's work has been about trying to help people. not die of cancer. And if somebody brought me a great idea to like help people not if you know some seven year old didn't doesn't have to die of leukemia and it comes from Shanghai, I don't care. You know, I I want to make progress for patients, and so I'll look at an asset from anywhere. And as I said, there there really are some, you know, for example, there's a there's a company in China that's gotten very good at this DNA encoded library. technology. If you know that technology, it's a way to screen small molecules against a target and you can do like trillions at a time. So it's an innovative chemical biology approach. This company doesn't really have the wherewithal to turn these binding molecules into drugs. So they but they they are good at finding the first step of drug discovery. So if a company like that you know wanted to uh outlicense some of its initial hits, you know, and with the proviso that all of these things are probably going to fail, right? You know, most early stage drug discovery doesn't
21:22John Stanford: absolutely
21:22Unidentified speaker (speaker_1): right. So this is not a slam dunk sure bet, but you know, if a company like that doesn't want to start a Chinese new code but wants to license that to a US biotech company or a venture capitalist capitalists in the American United States like me, you know, that that that could be good for patients. I don't think we mind. we that kind of thing happening. And and of course, you know, if they they have a way of you know drugging some target that we've wanted to drug for years and have never been able to do because you know medicinal chemistry just hasn't been adequate, of course we should look at that asset. So yeah, no, I I I think that that's uh one of example of many ways where it's in our benefit it's in our interest to work with you
21:59Unidentified speaker (UNKNOWN): know
21:59Unidentified speaker (speaker_1): scientists in China.
22:00Unidentified speaker (UNKNOWN): Well
22:00John Stanford: I'm glad I I'm glad you said that and brought your personal history, which is is is pretty unassailable from the perspective of being patient first. And I will give credit to Treasury, um, who in drafting this rule, I really think they want strong feedback. They want conversations like this. And and the evidence point to that is, unlike any of the other sections, AI, quantum, hypersonic missiles, they said, look, we know what we're providing. proposing here may harm US health and it may harm the US economy.
22:33Unidentified speaker (UNKNOWN): And
22:33John Stanford: I think you're right. I think that's a tough sell. I think at the end of the day, we're patients before we're isolationists. And if there's a good medicine over there, or even the beginnings of a new medicine over there, we want it over here. I wanna want to
22:47Unidentified speaker (UNKNOWN): I
22:47John Stanford: wanna run something on the economic front because I think you hit the patient side so well. But putting on the investor hat, we've been talking about what we're calling the candid ratio. And so even if you set aside the patient stuff and what I consider some ethical concerns trying to slow down other people's discovery, if we looked at the candid UCB numbers and we looked at the upfront Front cash into China, because I think they're look, it is a policy question to say how much more. money, how much US capital should go anywhere around the world, but it particularly to an adversarial country. And we've tried to myth bust this idea of 120 billion. Those are bio bucks, they're not real. But we looked at the numbers for candid and the 50 million or so up front, and then against candid sale to UCB and the this set of investors, primarily. American in candid. And we found that for every dollar that went to China, 38 new dollars were created in the US
23:49and sort of contributing to that U.S. ecosystem. And we want to try to capture this concept of the candid ratio, as Is we're calling it. Um, does that Does that hold water with you from an economic standpoint of
24:02Unidentified speaker (UNKNOWN): we
24:03John Stanford: why would we not want the upside if if China is so willing to part with these assets, which of course they're starting to be less willing to part, why wouldn't we want the upside to land here versus Europe or Japan?
24:15Unidentified speaker (UNKNOWN): Yeah,
24:15Unidentified speaker (speaker_1): I mean, uh you know, I think that uh wait, so this is like the days of Adam Smith. We've known that trade is good in general for economic reasons. I I think that there are things that are uh can be done in China for a variety of reasons at much lower cost. You know, animal experiments, uh postdocs are much cheaper, you know, early stage chemists are much cheaper. And you know, if there's a strong competitive advantage to do, you know, and and the quality of those reagents are good, and they they, as I said, they are now good there, then of course it's uh uh you know good for American investors to make use of this uh lower cost uh tool for drug discovery. Drug discovery is horrifically expensive and it's you know rife with failure. And if you can shave a little bit of uh some of the early stage costs off, uh you know, that's gonna be good for American investors. So I I you know your numbers don't feel crazy to me. I think that uh you know, the the as I said, the the successful investors that I know in the United States doing biotech all have some relationship. with China. But you know, they even if they're still very committed, like I am, to starting US companies and finding true US innovation, uh, you know, the ability to work with uh you know other countries including China, and but it's also important, you know, Australia, Europe. I mean, there there are legitimate research capabilities beyond China that are val very valuable to the US. And so I I think that, you know, protectionist measures and
25:35say we've got to build it all at home is uh you know it's just not the right way. to go. It's not, it's not a good thing to be telling patients that that's our priority. And I don't think it's good for investors either. But you know, it is important that I always have to say when in this discussion that,
25:49Unidentified speaker (UNKNOWN): you know,
25:50Unidentified speaker (speaker_1): certainly in in academia, when uh the NIH began to crack down on sort of covert relationships between the Chinese government and American scientists, there was this pushback from academia that, hey, you guys are exaggerating. this isn't a real problem, that's a fictional thing. And that is not true. I mean, there is some legitimately very bad behavior. Some of it's state-sponsored with regard to the development of intellectual property, the protection of intellectual property. There's sort of regulatory tariffs that the Chinese government has put in place. There's, you know, there's this these sort of egregious, you know, spy episodes like in the news today with uh you know NVIDIA. So I so I I I think that, you know, China has been a bad actor when it comes to intellectual property in in some ways. And and it it would be really good if they stopped doing that. You know, if they um became more like uh our European partners, you know, trusted partners that don't steal our IP, uh that would be that would you know, in some ways, th these examples are very bad for the relationship and really empower the protectionists. who want to want to clamp down. And, you know, I one thing China could do that would be very meaningful, and I'm amazed they really haven't embraced this yet, is they could allow more unannounced inspections by the FDA. You know, that this is one of the reasons why FDA doesn't totally trust Chinese clinical trials, is because you know, the the inspectorate really can't get into
27:09China in a uh un unannounced way the way it can in just about every other country the FDA regulates. trials on with you know with a few other exceptions, but for the most part in Europe and Australia and Latin America, uh FDA inspectors you know can go in and and look for look at the d in original data uh with no prior notice. And you know, i if China really wants to be part of the international drug discovery, you know, uh equipment, they they should be uh you know more like the rest of the uh of the world.
27:36John Stanford: Hey Dad I'm I'm going back to just sort of the episode of the CIA visits Dr. Sharpless. I think that could uh that could make a great episode someday when your career is documented. And I think you're I think you hit on a really good point that there are behaviors that feed the protectionist voices. I wouldn't say they're pulling the right lever here, but their desire to pull A. lever in the midst of all of this, and and uh it is certainly a week of covert and espionage and and bad actors out of China. So uh I I think it's also it would be foolhardy for industry to dismiss that there's a a problem here, uh even if coins isn't the right fit. This is something we need to be talking about. I want to spin up slightly northern. a little further north in the Pacific, and um touch quickly on you and I both uh our paths didn't cross, but we were both in Japan over the last month. What took you to Japan? What and what were some of your takeaways about their budding entrepreneurial ecosystem?
28:41Unidentified speaker (speaker_1): Yeah, so I've I've long been an advisor, uh not a fiduciary advisor, just a a friend of the company of ChuGai Pharmaceuticals, which is an innovative uh Japanese company. company that
28:53Unidentified speaker (UNKNOWN): you know is
28:54Unidentified speaker (speaker_1): disease area non specific. And it it's it's really um
28:58Unidentified speaker (UNKNOWN): I
28:59Unidentified speaker (speaker_1): I like this role a lot because they have uh uh a somewhat different model from the United States. So they rely on most of their early drug discovery work to occur in in-house. house. So, you know, Japanese scientists employed by Chugai make these medical. medicines. There's this
29:16Unidentified speaker (UNKNOWN): uh
29:16Unidentified speaker (speaker_1): Japanese cultural emphasis on quality. You know, they they uh enormous.
29:22Unidentified speaker (UNKNOWN): And
29:22Unidentified speaker (speaker_1): uh some Japanese scientists from Chugai recently won the Lasker Award for the development of a medicine called HimLibra, which is uh uh a bi-specific antibody that replaces factor VIII for hemophilia. So very complicated product that you know who would have thought an antibody, a bi-specific antibody. could replace a blood clotting factor? I think, you know, those of us who thought about hemophilia, you know, a decade ago all always assumed gene therapy was going to be the answer. And that turns out to be impractical and difficult and very expensive. And that, you know, this solution is uh you know uh much simpler and is working really, really well. So that that medicine is making tremendous money uh for that company, but it's also benefiting many, many patients with hemophilia with factor eight deficiency. But you know, i in in in making that molecule, they screen something like 10,000 versions. I mean, it was the most worked over, you know, and it's you know, i and in in the in in American early stage biotech, it's not like that. You know, we you know rush and you know try and get in the clinic as quic quickly as possible, and you know, no one has the budget to sort of uh you know, you know, do that. So seeing this other way of uh building
30:27great medicines and a protracted, uh, you know, high emphasis on the performance of the molecules uh with you know uh a large scientific team that are devoted to projects over years is is uh interesting. It is the you know, it's the way Big Pharma used to make medicines in the United States in the 1990s. Uh Big Pharma now largely you know, outsources a lot of their science and and and acquires you know, early stage biotech. companies uh for innovation. But it's uh it's it's good to see and it's good to talk to those kinds of scientists. So I enjoy that job very much. And uh, you know, they they they're a company that has um
31:03Unidentified speaker (UNKNOWN): a
31:03Unidentified speaker (speaker_1): lot of interest in oncology and other areas, and so hearing what they think are you know sort of cutting-edge ideas is very For valuable to me. meat.
31:09John Stanford: It's such a great anecdote of something that I see more broadly when we take these delegations. of U.S. investors who haven't had a lot of experience exploring the Japanese ecosystem. The Japanese government always is very kind, rolls out the red carpet because they want this to take off. You know, I in the United States, entrepreneurs, not just in biotech, but anywhere, everybody shouts that they have something new that's different, that's going to be disruptive. Uh it's so antithetical to raise your hand over there and disrupt the harmony. And so when someone is willing to do it in Japan, I tell the investors, take note. If someone says they really have something here, they have done the homework to raise their hand and say, I've got a different path here. So I I I love that story out of Chu Gai. And I and I love the in yes, it's great that we have this sort of biotech. to be acquired model but it's also great to hear stories out of the RD from some of the big the big manufacturers as well. Aaron
32:09Unidentified speaker (UNKNOWN): Ross
32:09John Stanford: Powell
32:09Unidentified speaker (speaker_1): Yeah and it it's very interesting talk to them about their relationship with you know Singapore and China and uh Korea and Australia and how they're thinking about you know these changing secular patterns in drug discovery and and uh you know I think they they um have appreciated they, you know, they have this problem that I mentioned, that they they don't have the wealth of foreign scientists who want to come to Japan and work in Japanese labs, and and they see that as a real problem. They they realize they need to acquire international talent. As I said, this is, I think,
32:42Unidentified speaker (UNKNOWN): a
32:42Unidentified speaker (speaker_1): big advantage the United States has over China at present. That you know, the best Italian and French and Turkish scientists want to come to the United States. They want to work in our labs. And when we lose that advantage, we really will be in trouble. But Japan has thought a lot about this, about how to encourage sort of um you know scientific immigration, if you will, and try and make uh you know in a welcoming society for uh immigrant scientists. And one of their solutions has to put a big RD facility in Singapore, which is a very, you know, it's which is just maybe not the solution you would have picked, but it's uh it works. I mean, it's a it's an international city that draws, you know, from all over Asia and Europe, and that they have a very international workforce there, and that's been very, very successful. And uh, you know, how to make Tokyo and Yokohama and Kyoto and Osaka more appealing is something they're still thinking through, but uh, you know, they they I think have intelligently realized that you know to be competitive, they're going to need to draw in uh great scientists. And then they really focus on training within the company, you know, making these people extremely well trained scientists who understand all aspects of drug discovery and
33:48very high quality workforce. And so I think there's some things about that model that are very interesting and worth watching, and certainly You know, they uh, you know, their feelings about these new trends and in, you know, medicine. medicinal chemistry and antibody development things are are really important to me because they I think they have such uh good scientific viewpoints.
34:10John Stanford: You've touched a few times on the importance and the advantage, frankly, that the U.S. has in an ability to attract thoughtful immigrants to come here and do incredible science. Um do you still feel are or are we holding on to that advantage? Certainly the last couple of years haven't been necessarily openly hospitable to the rest of the world to come and do that. And a lot of media has been made about we're we're losing scientists, we're losing X number of scientists a day, PhD numbers are down. Where what do you see? Are we do Are we still a beacon that is attracting people? into the country, or is this something we're gonna need to remediate in the near term?
34:55Unidentified speaker (speaker_1): You know, I mean it it's important to be careful here because I I think this is uh
35:00Unidentified speaker (UNKNOWN): this
35:00Unidentified speaker (speaker_1): being a destination for the brightest minds scientifically is really uh important in the United States, and we can never take that for granted. And we have to always
35:09John Stanford: work
35:09Unidentified speaker (UNKNOWN): to
35:10Unidentified speaker (speaker_1): be a welcoming country that you know can find funding for these scientists and can help them fit culturally. and and you know visa status, right? You know, things like you know, can they
35:19Unidentified speaker (UNKNOWN): work
35:19Unidentified speaker (speaker_1): here? And so so I think those are really important issues and they they've gotten a lot of discussion. But I also believe the uh you know the exodus of the brain drain from America that's in the media almost on a weekly basis, including like last week's New York Times, is just yeah, it's just yellow journalism. There's no other word for it. I mean, it's it's not really. true. Uh it's predicated on this belief that the NIH is imploding and isn't funding science anymore and people are having to go to France to get their grants funded. And it's just it's it's it's not really the reality that I experience on a daily basis. You know the United States is still a welcoming environment for uh scientists and it's still because you know because we have this great technology and this great culture that people enjoy. uh a place where the best and the brightest really want to come. So I I think that um
36:07Unidentified speaker (UNKNOWN): you
36:07Unidentified speaker (speaker_1): know the media uh reports of the demise of American science as a destination are really overblown. I, you know, I I think um when you really read these stories, it's often, you know, a a a European national finishes their postdoc and wants to go back to Europe. I mean that's always happened. You know, there's or you know they'd they have have kids kids and they want to move closer to grandma and she lives in the Netherlands, you know, things like that. Or, you know, a few, a few uh, you know, scientists have gone to Canada. But basically, uh in biomedical research at least, uh salaries are much higher here, grant funding is much easier to get, uh, the best technology is here. It's very free and open society where you can have whatever political beliefs you want, and you know, as long as within reason, uh you know you
36:50Unidentified speaker (UNKNOWN): know
36:50Unidentified speaker (speaker_1): you can fit. can fit in American culture. And you'll find, you know, whatever language you speak, there's a community in the United States that speaks it, right? I mean, we we are very welcoming to uh immigrants and foreigners. So I so I think that um you know it's gonna be tough for other countries to compete with that if they don't provide the funding for scientific research the United States provides, and they don't provide you know the sort of milieu that the United States currently provides. You
37:13Unidentified speaker (UNKNOWN): know,
37:14Unidentified speaker (speaker_1): I I don't think we can be complacent and uh you know stop all H1B visas and things, or you
37:20Unidentified speaker (UNKNOWN): know,
37:20Unidentified speaker (speaker_1): charge $100,000 a visa or something. I
37:22Unidentified speaker (UNKNOWN): mean,
37:22Unidentified speaker (speaker_1): that I think that would be bad. But at the same time, uh this is still the primary destination for uh some of the best scientists in the world. And the people and and I and one of the reasons I believe this is because I work quite a lot with European investors and European. scientists, and they they are very frustrated. You know, they they continue to watch their hottest postdocs want to come to the United States because they can't, you know, the grant they can get in Germany is for $50,000 or something. You know, it's it's a tenth what they would get in the United States. So uh, you know, luckily, um the the and you know, frankly, again, this comes back to the NIH, you know, a lot of this support for early. stage science is made possible by the U.S. federal government, including, you know, as an attractive way to bring in foreign scientists. And uh so as I said, I think it's very important the NIH continue to enjoy the broad bipartisan support even after the Blue Wave.
38:18John Stanford: Well, let's talk about that blue wave. You've been incredibly generous with your time. I I I want to hit that in one other thing. So uh you know, not necessarily the the positive politics of it all. Obviously, Democrats will enjoy not just majorities, but strong majorities in both sides.
38:34Unidentified speaker (UNKNOWN): Um,
38:35John Stanford: as an investor, as a leader in the cancer field, as a leader in in biomedical development broadly.
38:41Unidentified speaker (UNKNOWN): How
38:41John Stanford: do you interpret that? We of course have Padufa coming up, and there was there was w you know, the letter is out there and don't need to get into the details, but how does what happened on election day in your mind potentially shift where conversations around staying competitive, Padoofah, access, how do how do you see those changing?
39:09Unidentified speaker (speaker_1): Administration, so I was carried over from Trump won to Biden. And so I I I I um
39:13Unidentified speaker (UNKNOWN): you know at least
39:14Unidentified speaker (speaker_1): with within the executive branch, I've seen both flavors of politics, and you know, that's probably the experience that made me a stark raving moderate. And I uh you know, I think there's some good ideas in the Democratic Party. I think you know certainly uh particularly the the sort of more moderate wing of the Democratic Party has been very strongly supportive of science and biomedical research. And you know, the i you know it's it's very hard for any. member of the Democratic Party to say something nice about big pharma. I mean, that's uh
39:42John Stanford: that
39:43Unidentified speaker (UNKNOWN): kind
39:43Unidentified speaker (speaker_1): of thing could cost you your job in the Democratic Party. But suppose it to say at least uh, you know, science, the NIH, venture capital, even the FDA, uh, you know, there's some there's certainly some good members of Congress who've been strongly supportive from the Democratic Party. And and so I think, you know, if the right group assumes leadership of these issues, uh, you know, things could be okay. I I do believe things like the NIH and the FDA benefit from divided government. You know, when there's a sort of one party in the White House and a different party running Congress, that generally forces some compromise. And things like the NIH, you know, which have broad bipartisan support, you know, benefit from compromise. Um, you know, it does cause this very practical and interesting issue that we have, you know, now uh you know a divided government. And and and I think that there are things in Congress and the executive branch that people would like to get done. And to get those things done is going to require, you know, compromise and discussion and governing skills that we haven't seen as much of over the last you know a few years. And and in particular, that means that you know, pieces of legislation that have to move, like Padufa or the appropriations bill, uh, you know, they become very important. I mean, they're always important, but now they're this, you know, Christmas tree where everyone wants to hang their ornament. And uh so I think we're gonna see a lot of stuff, you know, because these must-move pieces of legislation
41:03uh that could be uh really good or bad for American biotech. And and so I think you know, we've discussed the kind of protectionist leanings that are in Congress, and those are bipartisan. They are certainly not uh you know solely the party of one party. Uh similarly, you know, things like tariffs enjoy bipartisan support. And and and so, you know, whether we um
41:26Unidentified speaker (UNKNOWN): you know
41:27Unidentified speaker (speaker_1): get good policies that would support the NIH and American biomedical research and the FDA or policies that would you know would sort of create problems, we'll we'll see. But I think uh you know, my my overall overarching belief is that
41:41Unidentified speaker (UNKNOWN): uh
41:41Unidentified speaker (speaker_1): divided government forces compromise, and compromise is good for something like the NIH.
41:46John Stanford: Yeah, I would hope that it offers continuity. We don't we don't need revolutionary ideas. I'll say I won't I won't force you to go on record about it. We don't need an expansion of IRA. We don't need spillover into the commercial market. We don't need to deepen the pill penalty, um, but we will tackle those uh as they come up in the new Democratic Congress. All right, last question, uh, and that is I I I don't know that you set Google alerts after yourself, but uh there was some media earlier this year, your name floating around um as a possible candidate for the next FDA commissioner. And I want to live in that parallel world for a moment. Um If that was something that you did take and you were in that role, how do you navigate the desire to really modernize the agency with the balance of pilot authority? Because the number one question I get is: yeah, I I d don't mind what the FDA is doing. I like trial blazer, but I don't have the certainty. And without Congress b backing some of the priority review stuff,
42:57Unidentified speaker (UNKNOWN): if
42:57John Stanford: it's not in statute, how would you let's let's live in the universe? We're sitting here with Commissioner Sharpless. Are you someone who would have leaned more into pilot authorities and trying stuff because Lord knows we need it? Or would you really try to get Congress to come along to give us more certainty and build maybe more of a 10, 15 year timeline to strengthen the agency?
43:21Unidentified speaker (speaker_1): Yeah. So in that alternate universe, first off, I'd be divorced. So there's spending a lot of time on hinge or whatever, but uh that we will go down that path. Uh yeah, I think um
43:34Unidentified speaker (UNKNOWN): you
43:34Unidentified speaker (speaker_1): know, my sense is that um a lot of the things from this administration, uh, you know, some of which I strongly support and agree with, but they're not really they're just done by proclamation, by executive order, by you know, the whim of whoever's in that job that day. And they won't have a life extension, you know, beyond you know, the a ne the next commissioner or you know, HHS Secretary could
43:57Unidentified speaker (UNKNOWN): do
43:57Unidentified speaker (speaker_1): away with these things. So, you know, an example of that would be uh, you know, the proclamation from the Secretary about enforcement discretion for peptides. You know, the secretary of HHS has basically said, you know, we're not gonna enforce the law around these peptides. And and you know, that's proved to this reaction of, oh, shriek horror, and you know, we're gonna allow these un you know, these these unregulated things on the market, which is bad. And I I I share that view, but at the same time, uh, you know, there's no statute or rule here. The second uh we have a new secretary, I suspect that uh you know the FDA could change. its mind about enforcement discretion. And you know, that can day that can really turn on a day. You know, that's basically sending out a
44:33Unidentified speaker (UNKNOWN): letter.
44:33Unidentified speaker (speaker_1): I mean, that could be a very quick process. So that so a decision like that really doesn't have longevity and staying power. And I thought the you know, the prior commissioners' effort to have this sort of new commissioner's priority review voucher thing is another thing like that, that uh, you know, uh uh uh uh the next commissioner may just decide they don't want to do that and it'll go away. So uh you know I I I I think if you want to be FDA commissioner really have an impact, you have to uh either try and get Congress to do what you want them to do, which is almost impossible, and you know, and certainly not uh not even strictly legal, right? You're only supposed to offer technical advice, not you know, tell not lobby Congress, but uh, you know, a more likely to work pro in you know a pathways to try and do some rulemaking. And so I I think things like trial blazer I really am excited about. I I I yeah,
45:20Unidentified speaker (UNKNOWN): you
45:20Unidentified speaker (speaker_1): know, I'm I'm a long-term uh skeptic of uh FDA proclamations. I I know you know why uh you know the communications office, the FDA likes to you know get ahead of itself sometimes. And and I remember seeing that when it came out initially and thinking this looks like mostly an NIH thing, you know, there's some real stuff in the NIH and the NCI, but you know, the NH. NIH and the NCI are pretty limited about what they can do for the regulation of clinical trials, and and you know, they can just provide funding for clinical trials, but you
45:45Unidentified speaker (UNKNOWN): know,
45:45Unidentified speaker (speaker_1): the what what are they really able to do? And the FDA commitment didn't seem very real to me.
45:50Unidentified speaker (UNKNOWN): But
45:50Unidentified speaker (speaker_1): then the IND pilot came out, and that that is a very good document, and I think it has a lot of good ideas in it. And you know, I think based on that pilot could lead to some uh guidance or perhaps even rulemaking. around uh you know this this entity that's created that document of a qualified research institute, the QRI, which is some third party the FDA can rely on to help do some of the regulatory processing for first and human trials. And that's that's a good idea. That would help us catch up with China and Australia and even Germany for guys. God. I mean, you know, when we we're our bureaucracy for first and demon human trials is worse than Germany, you know we have a problem. So I think that you know that that's an appealing idea that I think, you know, depending on how that pilot goes, should be, you know, encoded in some side of some sort of more formal document. You know, the the it is important to say in the real world that you know there's an FDA commissioner uh who's uh on the precipice of being confirmed, you know, Heidi Overton has had her hearing, uh, and it's really in this lame duck session down to about a bunch of members of the Republican Senate who have lost their elections and aren't going to be coming back. And uh it's impossible for me to predict what's going to happen. I think uh, you know, Kyle Diamantis, the acting commissioner, has done a very good
47:03job. But uh, you know, I can uh share the sympathetic thing that you don't want to be acting commissioner forever. You know, it's
47:10John Stanford: a very
47:11Unidentified speaker (UNKNOWN): difficult
47:12Unidentified speaker (speaker_1): job for acting. So you know I I presume presume Kyle. Kyle at some point is going to want to move on. And the FDA is going to need a confirmed commissioner. I think Heidi's qualified. She has uh you know the trust of the president. She's acceptable to the uh certain members of Congress. So, you know, I hope I she'll get a vote. You know, I I don't know how Congress will vote. I don't know if those those members will support her, but I I think. people ought to at least say yay or nay for the president's pick who is, you know, otherwise qualified candidate. And uh you know, w the FDA benefits strongly from having a confirmed commissioner. So, you
47:48Unidentified speaker (UNKNOWN): know,
47:48Unidentified speaker (speaker_1): Scott Gottlieb and Mark McClellan wrote this op-ed about her, and I basically agree with you know that document, which says that it's uh better for the FDA to have some idea of who their leader's gonna be and have the support of a Senate confirmation. So, you know, so I but I think uh you know my advice to any new commissioner or what I would have done in the uh in the you know the uh in the alt alt world of sharp you know Sharples Commissioner is I'd be very worried about these non-medical product issues that are so consuming to the American public that can really cause a lot of political trouble for the commissioner like food and tobacco and blueberry flavored vapes. and miphipristone. I'll even put that one in, even though it is a medical product. You know, those are things that I think can really derail uh
48:35Unidentified speaker (UNKNOWN): you
48:35Unidentified speaker (speaker_1): know the commissioner's office. And um they certainly are uh look like they're many of these issues look like they're ripe to explode at the moment, with uh you know, former Maha people leaving the government and now going on social media saying about. a bunch of bad things about the White House and vice versa. And uh, you know, it looks like there's some unresolved tension with inside uh, you know, the supporters of RFK and and the president. And um, you know, those problems could be very destructive for the commissioner uh if they aren't handled correctly. And and you know, you know, and and the the problem is while while in my world we're so focused on things like accelerating. accelerated approval and pidufidates and you know yeah
49:17Unidentified speaker (UNKNOWN): you
49:17Unidentified speaker (speaker_1): know, project trial trialblazer and these sorting weedy clinical issues, you know, the American public cares about cat food. You know, they're they're very worried about, you know, is the is the lettuce safe to eat? Uh is uh you know what what kind of vape product can my child buy By at the gas station? You know, these kinds of questions the FDA regulates as well, and they are politically contentious.
49:38John Stanford: It it is a great reminder for all of us to to zoom out and see the bigger picture. Unresolved tension would be a great podcast name. Uh Ned, thank you. Um what an incredible conversation. We'll look forward to having you back on. Congratulations uh on the new role. And uh we're really grateful for the insights you shared with us today. Yeah,
49:59Unidentified speaker (speaker_1): it's great, great to be on again, and and thanks for the discussion. And uh it'll be interesting times. We'll see what happens the next couple of months. It's a good time to be a health policy walker.
50:08John Stanford: That's that's exactly right. Thank you. That wraps up this episode of the Making Medicine Podcast. Thanks again to Ned for coming back on the show and for his perspective on everything from early stage investing in China to what Congress has to tackle next year.
50:23Unidentified speaker (UNKNOWN): You
50:23John Stanford: can learn more about his work at HatterasVP.com. and make sure you subscribe to our channel for more future conversations. Thanks for listening, and as always, keep innovating.